SCHEMBL3305577

SCHEMBL3305577

Cc1ccccc1-n1nc(C)c(-c2ccc3nccnc3c2)c1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 11/20 0.58
ADORA3 P0DMS8 1/20 0.52
HTT P42858 2/20 0.50
KMT2A Q03164 1/20 0.50
ADORA2B P29275 2/20 0.47
MAPT P10636 5/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 6/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
ADORA2A P29274 1/20 0.41
TP53 P04637 2/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
GLA P06280 2/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974032 0.78 SMN1; SMN2 (0.54) ADORA1HTTKMT2AMAPTALDH1A1
SCHEMBL3303329 0.78 ADORA1 (0.58) ADORA1ADORA3HTTKMT2AADORA2B
SCHEMBL3302210 0.72 ADORA1 (1.00) ADORA1ADORA3ADORA2BADORA2A
SCHEMBL3304819 0.71 ADORA1 (0.80) ADORA1ADORA3ADORA2BADORA2A
SCHEMBL1819219 0.71 ADORA1 (1.00) ADORA1ADORA3ADORA2BADORA2A
SCHEMBL1819329 0.70 ADORA1 (0.72) ADORA1ADORA3ADORA2BADORA2A
SCHEMBL3866835 0.68 SMN1; SMN2 (0.58) HTTKMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1819331 0.68 HTT (0.60) ADORA3HTTKMT2AMAPTALDH1A1
SCHEMBL27751914 0.67 CLK4 (0.55) ADORA1KMT2AALDH1A1TP53MAPK1
SCHEMBL3683981 0.66 RAB9A (0.65) HTTKMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
WO-2010020363-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF CYP3A5, ABAT, TPMT ADORA1 724/4885ADORA3 168/4885HTT 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.